Journal article
Genome-wide evolutionary analyses of G1P[8] strains isolated before and after rotavirus vaccine introduction
M Zeller, C Donato, NS Trovão, D Cowley, E Heylen, NC Donker, JK McAllen, A Akopov, EF Kirkness, P Lemey, M Van Ranst, J Matthijnssens, CD Kirkwood
Genome Biology and Evolution | Published : 2015
DOI: 10.1093/gbe/evv157
Open access
Abstract
Rotaviruses are the most important etiological agent of acute gastroenteritis in young children worldwide. Among the first countries to introduce rotavirus vaccines into their national immunization programs were Belgium (November 2006) and Australia (July 2007). Surveillance programs in Belgium (since 1999) and Australia (since 1989) offer the opportunity to perform a detailed comparison of rotavirus strains circulating pre- and postvaccine introduction. G1P[8] rotaviruses are the most prominent genotype in humans, and a total of 157 G1P[8] rotaviruses isolated between 1999 and 2011 were selected from Belgium and Australia and their complete genomes were sequenced. Phylogenetic analysis show..
View full abstractGrants
Awarded by National Science Foundation
Funding Acknowledgements
We would like to thank David Wentworth, Rebecca Halpin, Nadia Fedorova, Timothy Stockwell, and Susmita Shrivastava for help with genome sequencing, assembly, and annotation. This work has been funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under contract number HHSN272200900007C. This work was supported in part by a grant from the National Health and Medical Research Council of Australia (1031473). This research was supported by the Victorian Government's Operational Infrastructure Support Program. M.Z. was supported by the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT Vlaanderen). C.D.K. is the director of Australian Rotavirus Surveillance Program, which is supported by research grants from vaccine manufacturers CSL and GSK, as well as the Australian Commonwealth Department of Health Department. The research leading to these results has received funding from the European Union Seventh Framework Programme [FP7/2007-2013] under Grant Agreement no. 278433-PREDEMICS and ERC Grant agreement no. 260864.